Buserelin - Pharm-Sintez

Drug Profile

Buserelin - Pharm-Sintez

Alternative Names: Buserelin; Buserelin depo - Pharm-Sintez; Buserelin nasal spray - Pharm-Sintez; Buserelin-depo; Gonadotropin releasing harmone analogue - Pharm-Sintez

Latest Information Update: 29 Oct 2015

Price : $50

At a glance

  • Originator Pharm-Sintez
  • Class Antineoplastics; Hormones; Infertility therapies
  • Mechanism of Action LHRH receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Breast cancer; Endometrial hyperplasia; Endometriosis; Infertility; Leiomyoma; Prostate cancer

Most Recent Events

  • 15 Mar 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top